Acknowledgement

This activity is provided by Talem Health and RME Collaborative.

This activity is supported by an independent medical education grant from Astellas and Pfizer, Inc.

Credit Available

• Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
• Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)
• Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for oncologists, urologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

Program Overview

Prostate cancer is the second-leading cause of cancer-related mortality and, among men, is the leading cause of cancer-related death in the United States. In rural and underserved communities, long travel distances, limited access to oncology specialists, and other barriers contribute to disparities in cancer screening, biomarker testing, and clinical trial participation, ultimately leading to poorer outcomes. This online, on-demand CME/CE activity will explore best practices for prostate cancer risk stratification, including the use of biomarkers, imaging, and genomic/genetic testing. Expert faculty will review current and emerging treatment options, as well as the supportive role of integrative medicine. Additionally, participants from a recent Prostate Cancer Project ECHO® initiative will share insights, challenges, and lessons learned from caring for patients with prostate cancer in rural and underserved settings. 

The content for this enduring activity was recorded on November 7, 2025.

Learning Objectives

Upon completion of this activity, participants should be better able to:  

• Describe risk stratification strategies in prostate cancer including use of biomarkers, imaging, and genomic/genetic testing
• Assess evolving treatment approaches for nonmetastatic hormone-sensitive prostate cancer, metastatic hormone-sensitive prostate cancer, nonmetastatic castration-resistant prostate cancer, and metastatic castration-resistant prostate cancer
• Apply clinical evidence to personalized treatment approaches in patients with prostate cancer
• Implement strategies to improve coordination of care and increase use of shared decision-making to overcome barriers to prostate cancer care in rural and underserved settings

Faculty

Alicia K. Morgans, MD, MPH 
Associate Professor of Medicine
Harvard Medical School
Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, MA

Mark A. Preston, MD, MPH
Associate Professor of Surgery
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement

Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Continuing Pharmacy Education
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education. 
(Universal Activity Number – JA4008332-0000-25-100-H01-P)
Type of Activity: Application

Disclosure of Conflicts of Interest

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated. 

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty

Alicia K. Morgans, MD, MPH, has disclosed the following relevant financial relationships: consultant/advisory board member for Astellas, AstraZeneca Pharmaceuticals, Bayer, Curium, Exelixis, Inc., Janssen Pharmaceuticals, Lantheus, MacroGenics, Inc., Merck & Co., Inc., Myovant Sciences, Myriad Genetics, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Sanofi, Sumitomo Pharma America, Inc., and Telix Pharmaceuticals; contracted research for Astellas, Bayer, Janssen Pharmaceuticals, and Pfizer, Inc.; Data and Safety Monitoring Board member for Bristol Myers Squibb.

Mark A. Preston, MD, MPH, has disclosed the following relevant financial relationships: steering committee for Bayer and Johnson & Johnson.

Planners, Managers, and Reviewer 

The Talem Health planners, managers, and reviewer have nothing to disclose.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME credit, participants must:

1. Read the CME/CE information, including learning objectives and disclosure statements.
2. Complete the pre-test.
3. View the online activity.
4. Complete the post-test and evaluation form.

A post-test score of 75% or higher is required to obtain credit. Your certificate will be made available for immediate download.

Course Viewing Requirements

Supported Browsers:
Desktop/laptop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge
Mobile devices: Newest and last prior version of Safari and Google Chrome

Supported Phones & Tablets:
All devices

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.

Media

Internet activity

Fee Information

There is no fee for this educational activity.

Contact Information

For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.